Stoke Therapeutics (NASDAQ:STOK) Cut to Sell at Wall Street Zen

Wall Street Zen lowered shares of Stoke Therapeutics (NASDAQ:STOK) from a hold rating to a sell rating in a report issued on Saturday morning.

A number of other research firms also recently commented on STOK. Wedbush boosted their target price on Stoke Therapeutics from $36.00 to $38.00 and gave the stock an “outperform” rating in a research report on Tuesday, March 17th. Needham & Company LLC raised their price target on Stoke Therapeutics from $35.00 to $40.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Loop Capital set a $35.00 price target on Stoke Therapeutics in a research note on Monday, January 5th. UBS Group set a $50.00 price objective on shares of Stoke Therapeutics in a research report on Monday, December 15th. Finally, Chardan Capital reissued a “buy” rating and issued a $35.00 price objective on shares of Stoke Therapeutics in a research note on Wednesday, March 18th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating and two have given a Hold rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average price target of $41.83.

Stoke Therapeutics Price Performance

STOK opened at $33.40 on Friday. Stoke Therapeutics has a 1-year low of $5.35 and a 1-year high of $40.22. The stock has a market cap of $1.98 billion, a P/E ratio of 49.85 and a beta of 1.07. The stock’s 50 day simple moving average is $32.69 and its 200 day simple moving average is $30.26.

Insider Activity

In related news, General Counsel Jonathan Allan sold 4,628 shares of the stock in a transaction on Wednesday, March 18th. The stock was sold at an average price of $31.34, for a total transaction of $145,041.52. Following the sale, the general counsel owned 28,836 shares of the company’s stock, valued at $903,720.24. This trade represents a 13.83% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Jason Hoitt sold 1,931 shares of the stock in a transaction on Wednesday, March 18th. The shares were sold at an average price of $31.34, for a total value of $60,517.54. Following the sale, the insider directly owned 10,276 shares in the company, valued at approximately $322,049.84. The trade was a 15.82% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 69,699 shares of company stock worth $2,526,714 in the last quarter. 9.50% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Kestra Advisory Services LLC acquired a new stake in shares of Stoke Therapeutics during the 4th quarter worth about $26,000. Harbour Investments Inc. raised its position in shares of Stoke Therapeutics by 312.9% in the fourth quarter. Harbour Investments Inc. now owns 1,185 shares of the company’s stock valued at $38,000 after buying an additional 898 shares during the last quarter. Generali Investments Management Co LLC purchased a new position in shares of Stoke Therapeutics during the third quarter valued at approximately $41,000. Mirae Asset Global Investments Co. Ltd. boosted its position in Stoke Therapeutics by 31.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,776 shares of the company’s stock worth $88,000 after acquiring an additional 658 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its stake in Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company’s stock worth $48,000 after acquiring an additional 1,668 shares during the period.

Stoke Therapeutics Company Profile

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.